Capricor Therapeutics (CAPR) Falls On FDA Doubts, Where Does Fair Value Sit?

Simply Wall St.

Jul 29

Capricor Therapeutics (CAPR) is under intense scrutiny after FDA briefing documents questioned the efficacy and statistical analysis of Deramiocel for Duchenne muscular dystrophy, triggering a sharp ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2655894328"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2655894328\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2655894328?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-29 23:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655894328","market":"nz","top_or_hot":-1,"title":"Capricor Therapeutics (CAPR) Falls On FDA Doubts, Where Does Fair Value Sit?","media":"Simply Wall St.","content":"<div>\n<p>Capricor Therapeutics (CAPR) is under intense scrutiny after FDA briefing documents questioned the efficacy and statistical analysis of Deramiocel for Duchenne muscular dystrophy, triggering a sharp ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-capr/capricor-therapeutics/news/capricor-therapeutics-capr-falls-on-fda-doubts-where-does-fa\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Capricor Therapeutics (CAPR) Falls On FDA Doubts, Where Does Fair Value Sit?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCapricor Therapeutics (CAPR) Falls On FDA Doubts, Where Does Fair Value Sit?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-29 23:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-capr/capricor-therapeutics/news/capricor-therapeutics-capr-falls-on-fda-doubts-where-does-fa><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Capricor Therapeutics (CAPR) is under intense scrutiny after FDA briefing documents questioned the efficacy and statistical analysis of Deramiocel for Duchenne muscular dystrophy, triggering a sharp ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-capr/capricor-therapeutics/news/capricor-therapeutics-capr-falls-on-fda-doubts-where-does-fa\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-capr/capricor-therapeutics/news/capricor-therapeutics-capr-falls-on-fda-doubts-where-does-fa","article_id":"2655894328","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-capr/capricor-therapeutics/news/capricor-therapeutics-capr-falls-on-fda-doubts-where-does-fa","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2655894328","pubTimestamp":1785337953,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Capricor Therapeutics (CAPR) is under intense scrutiny after FDA briefing documents questioned the efficacy and statistical analysis of Deramiocel for Duchenne muscular dystrophy, triggering a sharp share price drop and multiple law firm investigations.\nSee our latest analysis for Capricor Therapeutics.\nThe latest FDA briefing has sharply changed sentiment around Capricor Therapeutics, with the share price falling 66.8% over the past week and 76.8% year to date. At the same time, the 3 year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LABU":"三倍做多标普生物-Direxion","CAPR":"Capricor Therapeutics Inc","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Capricor Therapeutics (CAPR) 陷入 FDA 怀疑，公允价值在哪里？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"CAPR":1.5},"content_text":"Capricor Therapeutics (CAPR) is under intense scrutiny after FDA briefing documents questioned the efficacy and statistical analysis of Deramiocel for Duchenne muscular dystrophy, triggering a sharp share price drop and multiple law firm investigations. See our latest analysis for Capricor Therapeutics. The latest FDA briefing has sharply changed sentiment around Capricor Therapeutics, with the share price falling 66.8% over the past week and 76.8% year to date. At the same time, the 3 year total shareholder return of 43.1% and 5 year total shareholder return of 47.6% show that long term holders have still seen gains despite the recent repricing of regulatory risk. If this kind of regulatory shock has you reassessing your watchlist, it can help to compare with other healthcare names using a focused screener for 40 healthcare AI stocks. After a drop that leaves Capricor Therapeutics trading at US$6.57, while analyst and intrinsic value estimates sit far higher, the real focus is where fair value now lies within such a wide spread. AdvertisementMost Popular Narrative: 88.7% Undervalued Capricor Therapeutics last closed at $6.57 while the most followed narrative sets fair value at $58. That gap reflects a very different view of what Deramiocel and the exosome platform could be worth if key assumptions play out.  The most compelling reason to look at Capricor right now is that Deramiocel is just the tip of the iceberg. An FDA approval functionally validates the therapeutic viability of the company's underlying exosome platform. Capricor is already leveraging this momentum to develop StealthX, a next-generation engineered exosome platform capable of carrying specific tissue-targeted genetic payloads, spanning from vaccines to oncological therapeutics.  Read the complete narrative. This narrative, shared by AnimalDoctorKwon, leans heavily on high projected revenue growth, a shift from losses to profitability, and a premium future earnings multiple that together help justify a fair value nearly nine times above the last close. It rests on specific assumptions about how fast exosome based therapies could scale, how margins might evolve, and how investors might value a successful platform company. Result: Fair Value of $58 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this Capricor Therapeutics narrative could be knocked off course if the FDA maintains concerns around Deramiocel, or if the NS Pharma dispute escalates. Find out about the key risks to this Capricor Therapeutics narrative. Next Steps Given the split between recent share price pressure and past gains for Capricor Therapeutics, it makes sense to move fast and check the data yourself. To balance the concerns and the potential upside, start with a clear view of the 2 key rewards and 3 important warning signs. Looking for more investment ideas beyond Capricor Therapeutics? If Capricor Therapeutics has you rethinking your next move, do not stop here. Use focused stock screeners to quickly spot ideas that better match your goals.  Target long term value potential by scanning for companies that combine quality fundamentals with discounted prices using the 49 high quality undervalued stocks. Strengthen your core holdings by filtering for businesses with sturdy finances through the solid balance sheet and fundamentals stocks screener (48 results). Hunt for tomorrow's opportunities before they hit the spotlight by checking the screener containing 20 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}